PNC Financial Services Group Inc. (The) Common Stock vs State Street SPDR S&P Biotech ETF — how do they compare? PNC Financial Services Group Inc. (The) Common Stock trades at $219.21 (market cap $87.64B), while State Street SPDR S&P Biotech ETF trades at $153.34 (market cap $10.11B). The key difference: PNC Financial Services Group Inc. (The) Common Stock is far larger — about 8.7× State Street SPDR S&P Biotech ETF's market cap, and PNC Financial Services Group Inc. (The) Common Stock pays a 3.64% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| PNC | XBI | |
|---|---|---|
Market Cap | $87.64B | $10.11B |
Volume | 1,687,662 | 12,903,266 |
Sector | Financials | Broad Market / Factor |
52-Week High | $256.97 | $169.55 |
52-Week Low | $178.37 | $104.99 |
Enterprise Value | $144.63B | — |
Dividend Yield | 3.64% | — |
Typical Hold Time | — | 37 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
PNC Financial Services Group is a financial services holding company. Its businesses include retail banking, corporate and institutional banking, and asset management.
Read more on PNC →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →